Clinicians have an opportunity to provide evidence-based care to this high-risk cohort and to aggressively treat the underlying atherosclerotic process through lifestyle modification and effective pharmacological In most cases, the inpatient anti-ischemic medi- cal regimen should be continued after discharge, and the anti- platelet/anticoagulant medications should be changed to an outpatient regimen. The goals for continued medical therapy after discharge relate to potential prognostic benefits (primar- ily shown for antiplatelet agents, beta blockers, statins, and inhibitors of the renin-angiotensin aldosterone system, espe- cially for LVEF <0.40).Added benefits are control of ischemic symptoms (nitrates, beta blockers, CCBs, and ranolazine) and treatment of major risk factors such as smoking, hypertension, dyslipidemia, physical inactivity, obesity, and diabetes mel- Selection of a medical regimen should be individual- ized to each patient on the basis of in-hospital findings, risk factors for CAD, drug tolerability, and recent procedural inter- ventions. The mnemonic ABCDE (Aspirin, Antianginals, and ACE Inhibitors; Beta Blockers and BP; Cholesterol and Cigarettes; Diet and Diabetes Mellitus; Education and Exercise) is useful in guiding treatment.428 6.2. Medical Regimen and Use of Medications at Discharge: Recommendations Class I 1. Medications required in the hospital to control isch- emia should be continued after hospital discharge in patients with NSTE-ACS who do not undergo coro- nary revascularization, patients with incomplete or unsuccessful revascularization, and patients with re- current symptoms after revascularization. Titration of the doses may be required.427,428 (Level of Evidence: C) 2. All patients who are post NSTE-ACS should be giv- en sublingual or spray nitroglycerin with verbal and written instructions for its use.429 (Level of Evidence: C) 3. 